The revision of the pharmaceutical legislation — it is time to act for nuclear medicine in Europe-Reference-Cited by-同舟云学术

The revision of the pharmaceutical legislation — it is time to act for nuclear medicine in Europe

Published:2023-10-23 Issue:1 Volume:51 Page:20-24
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Patt Marianne,Decristoforo Clemens,de Martini Amélie,Koole Michel,Oyen Wim J. G.,Kiss Oliver C.^ORCID

Funder

Helmholtz-Zentrum Dresden - Rossendorf e. V.

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging,General Medicine,Radiology, Nuclear Medicine and imaging,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00259-023-06472-1.pdf

Reference13 articles.

1. Deutsch E. Clinical PET: its time has come? J Nucl Med. 1993;34(7):1132–3.

2. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48(4):508–18.

3. Krenning EP, Kwekkeboom DJ, Valkema R, Pauwels S, Kvols LK, De Jong M. Peptide receptor radionuclide therapy. Ann N Y Acad Sci. 2004;1014:234–45.

4. Hennrich U, Eder M. [177Lu]Lu-PSMA-617 (PluvictoTM): the first FDA-approved radiotherapeutical for treatment of prostate cancer. Pharmaceuticals (Basel). 2022;15(10):1292.

5. Council Directive 89/343/EEC of 3 May 1989 extending the scope of Directives 65/65/EEC and 75/319/EEC and laying down additional provisions for radiopharmaceuticals. Official Journal of the European Communities. 1989. http://data.europa.eu/eli/dir/1989/343/oj/eng. Accessed 27 Aug 2023.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Guardians of precision: advancing radiation protection, safety, and quality systems in nuclear medicine;European Journal of Nuclear Medicine and Molecular Imaging;2024-02-06